Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBT (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBT for 6 consecutive years, with -$23.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 33.82% to -$23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$129.8 million through Dec 2025, down 2.66% year-over-year, with the annual reading at -$129.8 million for FY2025, 2.66% down from the prior year.
  • EBT for Q4 2025 was -$23.0 million at TScan Therapeutics, up from -$35.7 million in the prior quarter.
  • The five-year high for EBT was -$7.9 million in Q1 2021, with the low at -$37.0 million in Q2 2025.
  • Average EBT over 5 years is -$23.0 million, with a median of -$22.8 million recorded in 2023.
  • The sharpest move saw EBT crashed 120.91% in 2021, then soared 33.82% in 2025.
  • Over 5 years, EBT stood at -$14.2 million in 2021, then plummeted by 31.85% to -$18.7 million in 2022, then fell by 4.75% to -$19.6 million in 2023, then tumbled by 77.02% to -$34.7 million in 2024, then skyrocketed by 33.82% to -$23.0 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$23.0 million, -$35.7 million, and -$37.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.